FierceBiotech 2026-02-05 Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA
Endpoints News 2026-02-05 #ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
FierceBiotech 2026-02-05 GE HealthCare posts higher full-year revenues amid turbulent tariff backdrop
Endpoints News 2026-02-05 Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex
Illumina 2026-02-05 Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - Investing.com